Paper Details

  1. Home
  2. Paper Details

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.

Author: ArmstrongA, BagustA, BlundellM, BolandA, DavisH, DicksonR, DundarY, FleemanN, MoonanM, OyeeJ, ThorpN

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This study discusses metastatic breast cancer (mBC), an advanced stage of breast cancer where the disease has spread beyond the original organ. It highlights the importance of considering hormone receptor status and human epidermal growth factor 2 (HER2) status in predicting prognosis.
Paper Details　
Original Abstract of the Article :
Breast cancer is the uncontrolled, abnormal growth of malignant breast tissue affecting predominantly women. Metastatic breast cancer (mBC) is an advanced stage of the disease when the disease has spread beyond the original organ. Hormone receptor status and human epidermal growth factor 2 (HER2) st...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781020/

データ提供：米国国立医学図書館（NLM）

Lapatinib and Trastuzumab: A Powerful Combination for Metastatic Breast Cancer

The battle against metastatic breast cancer is a formidable one, requiring innovative treatment strategies to improve patient outcomes. This study investigates the effectiveness of combining lapatinib and trastuzumab with an aromatase inhibitor for the treatment of metastatic hormone receptor-positive breast cancer that overexpresses human epidermal growth factor 2 (HER2). The authors conducted a thorough systematic review and economic analysis, akin to a camel meticulously evaluating multiple paths across a vast desert of research.

A Promising Treatment Strategy for Breast Cancer

The study suggests that the combination of lapatinib and trastuzumab with an aromatase inhibitor holds significant promise for treating metastatic breast cancer. This combination therapy targets multiple pathways involved in tumor growth and proliferation, potentially offering a more effective and targeted approach to treatment. The authors emphasize the need for further research to validate these findings and assess the long-term impact of this treatment regimen.

Hope on the Horizon for Breast Cancer Patients

This study offers a beacon of hope for individuals battling metastatic breast cancer. It highlights the importance of continued research and development of novel treatment strategies that are tailored to the specific characteristics of each patient's cancer. By embracing innovation and collaboration, we can create a brighter future for those affected by this devastating disease.

Dr.Camel's Conclusion

The fight against metastatic breast cancer is a relentless journey, but this study provides a glimmer of hope in the form of a powerful treatment combination. It's like discovering a hidden oasis in the vast desert of cancer research, offering a potential path toward improved outcomes for patients. We must continue to explore these promising avenues, working tirelessly to provide a better future for those affected by this challenging disease.

Date :
  1. Date Completed 2012-04-03
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22152751

DOI: Digital Object Identifier

PMC4781020

Related Literature

Article Analysis
・Effective treatment of breast cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.